Atherosclerosis, cholesterol, nutrition, and statins--a critical review.
Atherosclerosis, which causes approximately half of all deaths of adults over age 60 in industrialized nations, is a pandemic among inappropriately nourished and/or physically hypoactive children, adolescents, and adults world wide. Although nowadays statins are widely prescribed to middle age and elderly adults with high blood lipid levels as pharmacological prevention for the late complications of atherosclerosis, from a critical point of view statins seem not to solve the problem, especially when compared with certain natural ingredients of our nutrition like micronutrients as alternative strategy. Statin ingestion is associated with lowering of serum cholesterol and low-density lipoprotein concentrations; some prospective studies have shown statistical associations with subsequent modest reduction of mortality from cardiovascular disease. However, specific biochemical pathways and pharmacological roles of statins in prevention of atherosclerosis, if any, are unknown. Moreover, there have been no systematic cost-benefit analyses of life-style prophylaxis versus statin prophylaxis versus combined life-style plus statin prophylaxis versus neither life-style nor statin prophylaxis for clinically significant complications of cardiovascular diseases in the elderly. Further, in the trials of effectiveness statins were not compared with management of nutrition, which is the most appropriate alternative intervention. Such studies seem to be important, as the ever increasing world population, especially in developing countries, now demand expensive statins, which may be unaffordable for mitigating the pandemic. Studies of this kind are necessary to identify more precisely those patients for whom cardiovascular benefits will outweigh the risks and costs of the statin treatment in comparison with nutritional interventions. Against the background of the current pathogenetic concept of atherogenesis some of its possible risk factors, particularly the roles of cholesterol and homocysteine, and the effects of statins versus nutritional (micronutrients) interventions in prevention and treatment of the disease are discussed. The prevailing opinion that serum cholesterol as a mediator of the disease is increased by eating saturated fats and decreased by eating polyunsaturated fats is being challenged. Evidently, the beneficial effects of statins in atherosclerosis are not mainly due to its cholesterol lowering effect, rather than to its "pleiotropic effects". Other pathogenetic factors in atherosclerosis are involved, like inflammatory and immunologic processes, that can be modulated by statins as well as by other drugs or by the Mediterranean-style nutrition and by micronutrients (folate, B-vitamins).
Gebbers
Jan-Olaf
JO
Institute of Environmental Medicine, Kantonsspital, Luzern, Switzerland. janolaf.gebbers@ksl.ch
Ann Intern Med. 2006 Jul 4;145(1):1-11
16818923
JAMA. 1999 Feb 24;281(8):727-35
10052443
Lancet. 2004 Jun 26;363(9427):2189-90
15220045
N Engl J Med. 2005 Jan 6;352(1):29-38
15635110
Ann Intern Med. 2006 Oct 3;145(7):520-30
17015870
Nervenarzt. 2003 Feb;74(2):115-22
12596012
J Am Coll Cardiol. 1998 Mar 1;31(3):552-7
9502634
Nat Med. 2000 Dec;6(12):1399-402
11100127
J Clin Endocrinol Metab. 2002 Feb;87(2):563-8
11836286
Annu Rev Pharmacol Toxicol. 2005;45:89-118
15822172
J Exp Med. 2004 Aug 16;200(4):541-7
15314078
Circulation. 1998 Mar 31;97(12):1129-35
9537338
Atherosclerosis. 1976 May-Jun;23(3):489-501
57782
JAMA. 1995 Oct 4;274(13):1049-57
7563456
Lancet. 2006 Jul 1;368(9529):83-6
16815382
Circulation. 1999 Feb 16;99(6):779-85
9989963
N Engl J Med. 2006 Apr 13;354(15):1601-13
16611951
Neurology. 2002 May 14;58(9):1333-7
12011277
Environ Health Perspect. 1994 Nov;102 Suppl 7:21-30
7889876
Circulation. 2002 Mar 26;105(12):1399-402
11914243
Lab Invest. 1968 May;18(5):623-8
5681205
Cardiovasc Res. 2001 Nov;52(2):299-305
11684078
N Engl J Med. 1996 Oct 3;335(14):1001-9
8801446
Circulation. 2006 Jan 3;113(1):74-80
16380544
J Clin Invest. 1993 Jan;91(1):308-18
8380812
Diabetologia. 2002 Jul;45(7):1004-10
12136399
N Engl J Med. 1999 Jan 14;340(2):115-26
9887164
Lancet. 2003 Jun 14;361(9374):2005-16
12814710
Int J Cardiol. 2004 Feb;93(2-3):175-9
14975544
J Cardiovasc Pharmacol. 2004 Mar;43(3):333-40
15076215
BMJ. 2005 Sep 17;331(7517):614
16107431
FASEB J. 1995 Jul;9(10):874-82
7615157
J Nutr. 2006 Jun;136(6 Suppl):1731S-1740S
16702348
Ann Intern Med. 2003 Nov 4;139(9):792-3
14597471
N Engl J Med. 2005 Jun 23;352(25):2573-6
15972861
JAMA. 2004 Sep 22;292(12):1440-6
15383514
Lancet. 2002 Jul 6;360(9326):7-22
12114036
N Engl J Med. 2005 Jan 6;352(1):20-8
15635109
JAMA. 2004 Dec 1;292(21):2585-90
15572716
Hypertension. 1999 Oct;34(4 Pt 2):987-96
10523396
Am J Pathol. 1969 Jul;56(1):111-28
5792556
Curr Opin Lipidol. 1997 Oct;8(5):301-11
9335954
Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6659-63
15096581
Arterioscler Thromb Vasc Biol. 2002 May 1;22(5):799-804
12006393
Am J Physiol Heart Circ Physiol. 2004 Jul;287(1):H1-7
15210447
J Nutr Biochem. 2004 Feb;15(2):64-79
14972346
Ann N Y Acad Sci. 2000 May;902:53-62; discussion 62-4
10865825
N Engl J Med. 1995 Nov 16;333(20):1301-7
7566020
Cell Metab. 2005 May;1(5):309-22
16054078
Am Clin Lab. 1997 Apr;16(3):14-5
10168016
Blood. 1990 Feb 15;75(4):895-901
2154269
JAMA. 2004 Sep 22;292(12):1433-9
15383513
J Intern Med. 2000 Mar;247(3):371-80
10762454
J Clin Invest. 2000 Aug;106(4):523-31
10953027
J Biol Chem. 2001 Jan 5;276(1):40-7
11022034